focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Share News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Whitbread Surges On Costa Coffee Sale

Fri, 31st Aug 2018 10:36

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - WINNERS----------Whitbread, up 16%. The hospitality firm said it agreed the sale of its Costa Coffee business to US soft drinks giant Coca-Cola Co at an enterprise value of GBP3.90 billion. Whitbread, which also owns the Premier Inn hotel chain, is expecting net proceeds of GBP3.80 billion, and said most of this will be returned to shareholders. The sale, the company continued, will reduce debt and also allow for an increased pension contribution and further expansion of Premier Inn in both the UK and Germany. Whitbread believes a "substantial" premium would have been created by its planned demerger of Costa Coffee, which was announced in April this year. At the time the company had described itself as "committed" to demerging Costa after the coffee chain saw a decline in annual profit.----------FTSE 100 - LOSERS----------Sage Group, down 6.5%. The accounting software provider said Chief Executive Officer Stephen Kelly has stepped down from his role with immediate effect. He is to "remain available to the group" until May 31, 2019. Kelly has been chief executive of Sage for nearly four years since 2014. The FTSE 100 group has started the process to find a new chief executive. Chief Financial Officer Steve Hare has been given the additional post of chief operating officer on an interim basis, giving him full authority to run the business until a new chief executive is appointed. In addition, Sage said it has continued to trade in line with its full-year guidance of 7.0% organic revenue growth and a 27.5% organic operating margin. The group said achieving this guidance is dependent on the closing of several Enterprise Management opportunities in September.----------Evraz, down 1.5%, Glencore, down 1.2%, BHP Billiton, down 0.9%. The commodity stocks were lower amid concerns that the US-Chinese trade dispute may intensify and over metal tariffs. US President Donald Trump said he could move ahead with a plan to impose tariffs on USD200 billion in Chinese imports as early as next week. In addition, Trump also threatened to pull out from the World Trade Organization and called European trade policies "almost as bad as China," raising fresh worries over trade friction.----------FTSE 250 - WINNERS----------Hays, up 6.4%. Shares in the recruiter were rebounding after it expressed uncertainty for its UK market due to economic instability, despite reporting positive results for its recently ended financial year on Thursday. The stock closed down 4.7% on Thursday. ----------FTSE 250 - LOSERS----------Serco Group, down 3.1%. Exane BNP downgraded the outsourcer to Neutral from Outperform.----------OTHER MAIN MARKET AND AIM - WINNERS----------Midatech Pharma, up 31%. The rare disease-focused pharmaceutical company announced positive data from its proof of concept exploratory study for its key oncology drug candidate MTD201. MTD201 Q-Ocreotide is a sustained-release treatment for carcinoid cancer and acromegaly. In a a double-blind exploratory study, the tolerability, pharmacokinetics and growth hormone profiles after a 30 milligram injection in 24 healthy subjects were compared between MTD201 and Novartis AG's Sandostatin LAR. Results from the study indicated that MTD201 produces a safe sustained-release profile of octreotide with growth hormone levels suppressed by an average of 25%, comparable with Sandostatin. Midatech will now seek regulatory approval for MTD201 as an equivalent product of improved product to Sandostatin in preparation for a follow-on trial.----------OTHER MAIN MARKET AND AIM - LOSERS----------FFI Holdings, down 27%. The entertainment industry contract provider said profit halved as costs associated with its recently listing hurt despite revenue jumping on acquisitions. For the year ended March 31, pretax profit halved to USD5.3 million from USD10.3 million the year prior. This was despite revenue rising to USD58.9 million from USD38.8 million the year before. Profit performance was hurt by a sharp rise in administrative and exceptional costs. Administrative expenses rose to USD29.4 million from USD18.9 million the year prior primarily driven by a jump in staff costs. Exceptional costs also rose to USD10.7 million from USD1.9 million the year before which was chiefly related to USD9.5 million in initial public offering costs.----------
More News
20 Sep 2019 13:30

Midatech Pharma Secures Approval To Commence MTD201 First-Phase Study

(Alliance News) - Midatech Pharma PLC on Friday said it has received approval to start a first phase of study on MTD201, which it is developing for the treatment of acromegaly and neuroendocrine a

Read more
11 Sep 2019 12:09

Midatech Secures Spanish Government Loan To Fund MTD201 Cancer Drug

(Alliance News) - Midatech Pharma PLC's shares surged on Wednesday as said it has received a EUR6.6 million loan from the Spanish government to finance manufacturing work in its facility in in

Read more
9 Sep 2019 12:20

Midatech Pharma Appoints Former Ergomed CEO As Chief Financial Officer

(Alliance News) - Immunotherapy-focused pharmaceutical company Midatech Pharma PLC said Monday it has appointed Stephen Stamp as chief financial officer with immediate effect.He will be who

Read more
31 Jul 2019 15:54

MidaTech Pharma Appoints Frederic Duchesne As Non-Executive Director

(Alliance News) - Midatech Pharma PLC said Wednesday that Frederic Duchesne had been appointed as a non-executive director, effective immediately.Duchesne was chief executive of the of May.

Read more
19 Jul 2019 12:21

Midatech Pharma Shares Surge After Positive Diabetes Treatment Results

(Alliance News) - Shares in biopharmaceutical firm Midatech Pharma PLC surged Friday after it received positive results from its first-in-human study of its MTX102 diabetes vaccine in Midatech 13%

Read more
3 Jul 2019 12:35

Midatech Adds Two Higher Dose Levels To MTX110 Brain Tumour Drug Study

(Alliance News) - Midatech Pharma PLC on Wednesday said two higher dose levels have been added to its study of brain tumour drug MTX110 as it has been well tolerated.Shares in the oncology

Read more
13 Jun 2019 16:20

Midatech Finalises Development Plan For Acromegaly Treatment MTD201

(Alliance News) - Midatech Pharma PLC on Thursday said it has finalised the development plan for MTD201 as a treatment in patients with acromegaly and neuroendocrine tumours using its Q-Sphera in

Read more
12 Jun 2019 16:04

UK Shareholder Meetings Calendar - Next 7 Days

Thursday 13 JuneTescoWM Morrison SupermarketsSirius MineralsJust Jack 14 Evans 17 18

Read more
24 Apr 2019 11:41

Midatech Pharma mired in losses as R&D costs mount

(Sharecast News) - Midatech Pharma's shares dropped on Wednesday as the company reported an annual loss and falling cash balances, though it remained confident in its ability to create value over the next 18-24 months.

Read more
24 Apr 2019 10:54

Midatech Pharma Loss Narrows As Revenue Rises Amid Refocused Business

LONDON (Alliance News) - Midatech Pharma PLC on Wednesday reported a narrowed annual loss on the back of increased revenue generation and said that the company has entered into a "new of US a

Read more
29 Mar 2019 10:40

WINNERS & LOSERS SUMMARY: TUI Hit By Grounding Of Boeing 737 Max Jet

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - up 2.5%, Glencore, up 2.6%,

Read more
29 Mar 2019 10:27

Midatech Pharma Shares Jump After Spanish Government Approves Loan

LONDON (Alliance News) - Midatech Pharma PLC on Friday said it received approval of a EUR6.6 million loan from the Spanish government for commercial scale-up of the company's cancer treatment

Read more
25 Feb 2019 15:49

Midatech Pharma Raises GBP13.4 Million In Placing And Open Offer (ALLISS)

LONDON (Alliance News) - Midatech Pharma PLC on Monday said it raised GBP13.4 million in a placing, subscription and open offer of shares at 3.85 pence each.Application has been made by the

Read more
4 Feb 2019 18:38

UPDATE: Midatech Raises GBP4.7 Million After Placing And Open Offer (ALLISS)

LONDON (Alliance News) - Midatech Pharma PLC said Monday it has raised GBP4.7 million via a share placing and open offer.Midatech said the placing and open offer was made at 3.85 pence for

Read more
4 Feb 2019 16:01

Midatech Seeks To Raise GBP4.8 Million From Placing And Open Offer (ALLISS)

LONDON (Alliance News) - Midatech Pharma PLC said Monday it intends to raise a minimum of GBP4.0 million from a share placing, plus up to GBPP750,000 from an open offer.Midatech, a research

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.